XenTech is pleased to collaborate with Cambridge Biomedical Inc (CBI), a laboratory CRO and diagnostic laboratory providing bioanalytical support to the pharmaceutical, biotechnology, and medical device industries.
XenTech and CBI have set up a partnership for the joint marketing of CRO services.
This new venture builds on XenTech’s patient-derived primary tumor Xenograft models combined with the experience of Cambridge Biomedical in bioanalytical assay development provides a cohesive offering from Development through to Phase IV.
We believe this collaboration will open up access to new customers in both the biotech and pharma sectors and allow both partners to cross-fertilize our customer portfolios in the US and Europe.
Since its establishment in 1997, Cambridge Biomedical supports sponsors and CRO’s developing customized assays for small and large molecules, biomarkers, diagnostics, and medical devices.
His team has expertise and extensive experience in technology transfer, assay development, optimization, and validation.
Cambridge Biomedical is positioned to work at preclinical, clinical, and post market stages of drug or device development. CBI has personalized project management, approach along with a focus on delivering quality results and regulatory submission ready documentation and rapid turnaround times, ensuring development timelines.